Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Suppository for treating mammalian endometritis and preparation method thereof

A technology for endometritis and mammals, applied in the direction of suppository delivery, medical preparations with non-active ingredients, medical preparations containing active ingredients, etc., can solve the problem of weak interaction of mucous membrane synovial fluid, unfavorable penetration into vaginal mucosa, Unsatisfactory bactericidal effect and other problems, to overcome the effect of irritation, strong bactericidal effect and long time

Inactive Publication Date: 2010-07-07
SHANGHAI HI TECH UNITED BIO TECHCAL RES
View PDF4 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] One of the technical problems to be solved by the present invention is to provide a biocidal suppository for treating endometritis in mammals, to overcome the unsatisfactory bactericidal effect, short retention time in the uterus, and synovial fluid contact with the prior art. The weak interaction is not conducive to the disadvantage of penetrating into the vaginal mucosa

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Suppository for treating mammalian endometritis and preparation method thereof
  • Suppository for treating mammalian endometritis and preparation method thereof
  • Suppository for treating mammalian endometritis and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Embodiment 1 Lysostaphin suppository preparation method 1 (prescription 1)

[0029] 1. Composition and ratio

[0030] Lysostaphin 0.001%, lysozyme 0.1%, sodium alginate 0.1%, chlorhexidine 0.5%, polyoxyethylene stearate 99.299%.

[0031] 2. Preparation

[0032] (1) First, add 2 grams of lysozyme and 20 mg of lysostaphin, 2 grams of sodium alginate and 1 gram of chlorhexidine into 100 mL of aqueous solution and mix evenly, then add dropwise to 5% calcium chloride solution to form particles, and filter Microparticles were obtained by freeze-drying.

[0033](2) The microspheres are placed in normal saline, and placed at 37° C. for 6-8 hours to detect the amount of lysozyme in the solution (the detection method refers to literature: Liu Yuangang et al., Determination of the activity of lysozyme, Food Science and Technology, 2005, 10), The encapsulation efficiency of lysostaphin and lysozyme contained in the microspheres was calculated. Calculate the amount of microparti...

Embodiment 2

[0035] Embodiment 2 Lysostaphin suppository preparation method 2 (prescription 2)

[0036] 1. Composition and ratio

[0037] Lysostaphin 0.05%, lysozyme 2%, sodium alginate 1%, chlorhexidine 0.3%, polyoxyethylene stearate 96.65%.

[0038] 2. Preparation

[0039] (1) First, add 2 grams of lysozyme and 50 mg of lysostaphin, 1 gram of sodium alginate and 0.6 gram of chlorhexidine into 100 mL of aqueous solution and mix evenly, then add dropwise to 5% calcium chloride solution to form particles, and filter Microparticles were obtained by freeze-drying.

[0040] (2) Measure the encapsulation efficiency of the prepared microparticles as in Example 1, calculate the amount of microparticles to be added according to the encapsulation efficiency, and then take an appropriate amount of microparticles and add them to the dissolved polyoxyethylene stearate.

[0041] (3) Weigh 96.65g of polyoxyethylene stearate and heat it to 60°C to dissolve, then add 3.35g of the prepared particles int...

Embodiment 3

[0042] Embodiment 3 Lysostaphin suppository preparation method 3 (prescription 3)

[0043] 1. Composition and ratio

[0044] Lysostaphin 0.1%; Lysozyme 10%; Sodium alginate 1%, Polyoxyethylene stearate 88.9%.

[0045] 2. Preparation

[0046] (1) First, add 20 grams of lysozyme, 200 mg of lysostaphin, and 10 grams of sodium alginate into 200 mL of aqueous solution and mix evenly, then add dropwise to 5% calcium chloride solution to form particles, which are obtained by freeze-drying after filtration particle.

[0047] (2) Measure the encapsulation efficiency of the prepared microparticles as in Example 1, calculate the amount of microparticles to be added according to the encapsulation efficiency, and then take an appropriate amount of microparticles and add them to the dissolved polyoxyethylene stearate.

[0048] (3) Weigh 88.9 grams of polyoxyethylene stearate and heat it to 60°C to dissolve, then add 11.1 grams of the prepared microparticles to the dissolved polyoxyethyle...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a suppository for treating mammalian endometritis and a preparation method thereof; the suppository comprises the following ingredients by counting total weight of the preparation: 0.001-0.1 percent of lysostaphin, 0.1-10 percent of lysozyme, 0.1-10 percent of sodium alginate tech grade, and 80.0-99.6 percent of polyoxyethylene ascorbyl stearate; by adopting the local administration mode, the mammalian endometritis can be effectively treated, the sterilizing effect is strong, the stability is good; in addition, in the processing process, as the lysozyme and the lysostaphin are packaged by the sodium alginate tech grade, so as to keep the activity of the enzymes in the suppository preparation process, lead the enzymes to be released in utero slowly and achieve better curative effect.

Description

technical field [0001] The invention relates to a biological bactericidal preparation, in particular to a biological preparation for treating mammalian endometritis. Background technique [0002] Endometritis is a common reproductive organ disease in mammals such as cows and pigs, and is one of the main causes of infertility in female animals. Seriously affect the reproduction and economic benefits of female animals. The main cause is artificial insemination, lax disinfection during childbirth or midwifery, improper postpartum care, etc. Invasive bacteria cause infection. In addition, vaginitis, uterine prolapse, retained placenta, etc., can all be secondary to endometritis. The main symptoms are: Acute generally occurs after abortion or when the placenta is retained, with elevated body temperature, loss of appetite, and depression. When it is severe, the back is arched, the shoulders are strained, and urination is often performed. Chronic is secondary to acute, and the es...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/48A61K9/02A61K47/34A61K47/36A61P15/00A61K31/155A61K47/14
Inventor 黄青山李国栋黄晋江
Owner SHANGHAI HI TECH UNITED BIO TECHCAL RES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com